Could kids with rare bone disease need less medicine?
NCT ID NCT07183579
Summary
This study is looking back at the medical records of children with XLH, a rare genetic condition that causes soft bones and growth problems. Researchers want to see if a lower starting dose of the standard treatment drug, burosumab, is just as good at controlling blood phosphate levels as the higher dose commonly used. The goal is to find the most effective dose with the least amount of medication for each child.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED HYPOPHOSPHATEMIA (XLH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nottingham University Hospitals NHS Trust
RECRUITINGNottingham, NG7 2UH, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.